Obesity: Pathology and Therapy

1. Front Matter

   Pages I-XXIII

   PDF

2. Pathology

   1. Front Matter

      Pages 1-1

      PDF

   2. Obesity: Definition and Epidemiology

      • M. DiGirolamo, J. Harp, J. Stevens

      Pages 3-28

   3. Health Implications of Obesity

      • F. X. Pi-Sunyer

      Pages 29-56

   4. The Molecular and Epidemiological Genetics of Obesity

      • Y. C. Chagnon, L. Pérusse, C. Bouchard

      Pages 57-89

   5. The Influence of Obesity on the Development of Non-Insulin-Dependent Diabetes Mellitus

      • J. W. Kolaczynski, B. J. Goldstein

      Pages 91-119

   6. Fat Metabolism in Obesity, with Special Emphasis on the Insulin Resistance and Elevated Lipid Mobilization in Visceral Obesity

      • P. Björntorp

      Pages 121-131

   7. The Regulation of Body Weight: Set-Points and Obesity

      • M. D. Hirvonen, R. E. Keesey

      Pages 133-151

3. Pharmacological and Other Treatments

   1. Front Matter

      Pages 153-153

      PDF

   2. Serotonin Drugs and the Treatment of Obesity

      • J. C. G. Halford, J. E. Blundell

      Pages 155-176

   3. Pharmacological Treatment of Obesity: Outcomes and New Tools

      • L. A. Campfield, F. J. Smith

      Pages 177-194

   4. Popular Diets and Other Treatments of Obesity

      • R. Konikoff, J. Dwyer

      Pages 195-236

   5. Diet and Body Weight Reduction

      • V. Drapeau, A. Tremblay

      Pages 237-258

   6. The Surgical Treatment of Morbid Obesity

      • D. M. Smith, W. J. Pories, K. G. MacDonald Jr

      Pages 259-291

4. Pharmacological Targets

   1. Front Matter

      Pages 293-293

      PDF

   2. Leptin: The Adipocyte Signal in the Control of Body Weight

      • J. F. Caro, M. E. Trautmann

      Pages 295-311

   3. Central Nervous System Neuropeptides Involved in Obesity

      • M. Rossi, S. R. Bloom

      Pages 313-341

   4. β3 Adrenergic Receptors as a Therapeutic Target for Obesity

      • J. G. Granneman

      Pages 343-367

   5. Insulin Sensitization

      • C. F. Burant

      Pages 369-400

5. Strategies for Indentifying Future Targets

   1. Front Matter

      Pages 401-401

      PDF

Obesity is a serious medical problem that affects millions of people, especially in Western societies. Although long considered a complicating factor in a variety of diseases, there is now widespread agreement that obesity itself should be classified and treated as a disease and that it has important conse­ quences for personal health, quality of life and cost to society. Understanding obesity and the means of treating it have been hampered in the past. There have been misperceptions that obesity is a behavioral disorder and that its treatments provides only cosmetic benefits. Pharmacologic approaches to treatment have suffered from problems of limited efficacy, reduced activity upon chronic use, and serious side effects, including abuse liability, cardiac disease, hypertension, and respiratory complications. Finally, there has been a proliferation of consumer and natural products with unproven benefits. This book attempts to address both the problems associated with obesity and the approaches to treating it. In the first section devoted to pathology, Drs. DIGIROLAMO, HARP, and STEVENS elaborate in Chap. 1 on how obesity and its medical complications develop. As described by Dr. PI-SUNYER in Chap. 2, obesity is a disease seen most often in affluent Western societies and is associated with the aforemen­ tioned medical problems, as well as Type II diabetes mellitus and gallbladder disease. Drs. CHAGNON, PERUSSE, and BOUCHARD review the human genetics of obesity in Chap. 3, and Drs.

• CNS
• Fettleibigkeit
• Pathology
• diabetes
• diabetes mellitus
• insulin
• insulin resistance
• lipide
• metabolism
• neuropeptides
• obesity
• pharmacology
• research
• resistance
• serotonin

• Department of Clinical Research, Parke-Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, USA

  Dean H. Lockwood

• Neuroscience Therapeutics, Parke-Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, USA

  Thomas C. Heffner

Policies and ethics